Literature DB >> 8453216

The risk of bilirubin encephalopathy, as estimated by plasma parameters, in neonates strongly suspected of having sepsis.

F Ebbesen1, A Knudsen.   

Abstract

The study comprises 18 mature newborns, strongly suspected of having sepsis, and a control group of 18 mature, healthy newborns with the same postnatal age. The object of the investigation was to compare the risk of development of bilirubin encephalopathy between the two groups, as estimated by plasma parameters. The sepsis group had significantly lower reserve albumin concentration for binding of MADDS (p < 0.01) and significantly lower total albumin concentration (p < 0.01). No significant differences were observed in unconjugated bilirubin concentration and plasma pH. It is suggested that mature newborns with sepsis have a slightly increased risk of developing bilirubin encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453216     DOI: 10.1111/j.1651-2227.1993.tb12509.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  4 in total

Review 1.  Bilirubin Binding Capacity in the Preterm Neonate.

Authors:  Sanjiv B Amin
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

2.  Low bilirubin kernicterus with sepsis and hypoalbuminaemia.

Authors:  Yetunde Odutolu; Anthony J Emmerson
Journal:  BMJ Case Rep       Date:  2013-04-23

3.  Transcutaneous bilirubinometry in neonatal intensive care units.

Authors:  A Knudsen; F Ebbesen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

4.  Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants.

Authors:  W Oh; D K Stevenson; J E Tyson; B H Morris; C E Ahlfors; G Jesse Bender; R J Wong; R Perritt; B R Vohr; K P Van Meurs; H J Vreman; A Das; D L Phelps; T Michael O'Shea; R D Higgins
Journal:  Acta Paediatr       Date:  2010-01-25       Impact factor: 2.299

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.